- NKTR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $24.6 million.
- NKTR has traded 356,119 shares today.
- NKTR is up 7.2% today.
- NKTR was down 6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in NKTR with the Ticky from Trade-Ideas. See the FREE profile for NKTR NOW at Trade-Ideas More details on NKTR: Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. Currently there are 7 analysts that rate Nektar Therapeutics a buy, 1 analyst rates it a sell, and none rate it a hold. The average volume for Nektar Therapeutics has been 1.5 million shares per day over the past 30 days. Nektar has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.46 and a short float of 13.5% with 5.81 days to cover. Shares are down 34.6% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Nektar Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Highlights from the ratings report include:
- Net operating cash flow has significantly decreased to -$24.63 million or 145.91% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The debt-to-equity ratio is very high at 6.99 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 4.16, which shows the ability to cover short-term cash needs.
- NKTR has underperformed the S&P 500 Index, declining 7.53% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Pharmaceuticals industry average, but is greater than that of the S&P 500. The net income increased by 4.1% when compared to the same quarter one year prior, going from -$47.66 million to -$45.68 million.
- NKTR, with its decline in revenue, underperformed when compared the industry average of 11.1%. Since the same quarter one year prior, revenues fell by 37.2%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- You can view the full Nektar Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.